Komori
ReproCELL (4978) · InitiativeAchieved

Offsetting the Deficit in Retained Earnings Brought Forward through Capital Reduction and Appropriation of Surplus

First written in FY2021. 4 of 9 entries say "Restated". Latest entry: FY2025-H1.

9entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q2 – FY2022-Q3RestatedFY2023-Q2 – FY2023-Q3AdvancedFY2024 – FY2025-H12021: 320212022: 320222023: 120232024: 22024
Same theme, other companies
Capital Policy and Dividend Preparation through Capital Reduction and Deficit EliminationA theme 287 companies write about · 1 as a headwind · 286 as a tailwind

127 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 289 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1AchievedAnnual report

    「In addition, the reduction of capital reserve and disposition of surplus (replenishment of deficit) carried out on 7 August 2024 reduced capital surplus by ¥501.924 million and increased retained earnings by ¥501.924 million.」

    The replenishment of the deficit using ¥501.924 million of capital reserve approved in FY2024 was carried out on 7 August 2024, completing the plan.
  2. FY2024AdvancedAnnual report

    「The reduction of capital reserve and disposition of surplus were approved at the 22nd Annual General Meeting of Shareholders held on 24 June 2024.」

    The shareholders' meeting approved a plan to transfer ¥501,924,485 of capital reserve to other capital surplus and appropriate it to replenish the deficit in retained earnings. The effective date was scheduled for 7 August 2024.
  3. FY2023-Q3RestatedAnnual report

    「In addition, the reduction of capital reserve and disposition of surplus (replenishment of deficit) carried out on 5 August 2022 reduced capital surplus by ¥540.274 million and increased retained earnings by ¥540.274 million.」

    The results of the replenishment of the deficit through the reduction of capital reserve and disposition of surplus carried out on 5 August 2022 are reconfirmed.
  4. FY2023-Q2RestatedAnnual report

    「In addition, the reduction of capital reserve and disposition of surplus (replenishment of deficit) carried out on 5 August 2022 reduced capital surplus by ¥540.274 million and increased retained earnings by ¥540.274 million.」

    The results of the replenishment of the deficit through the reduction of capital reserve and disposition of surplus carried out on 5 August 2022 are reconfirmed.
  5. FY2023-Q1AchievedAnnual report

    「At the 20th Annual General Meeting of Shareholders held on 24 June 2022, a resolution was passed concerning the reduction of capital reserve and the disposition of surplus, and the reduction became effective on 5 August 2022.」

    The measure to transfer ¥540,274,052 of capital reserve to other capital surplus and appropriate the same amount to replenish the deficit in retained earnings became effective on 5 August 2022.
  6. FY2022-Q3RestatedAnnual report

    「In addition, the gratuitous capital reduction and disposition of surplus (replenishment of deficit) carried out on 6 August 2021 reduced capital surplus by ¥2,557.316 million and increased retained earnings by ¥8,859.508 million.」

    The results of the replenishment of the deficit through the gratuitous capital reduction and disposition of surplus carried out on 6 August 2021, as well as the increase in retained earnings, are reconfirmed.
  7. FY2022-Q2RestatedAnnual report

    「The issuance of new shares upon the exercise of share acquisition rights increased stated capital and capital surplus by ¥335.766 million each during the six-month period ended 30 June 2021. In addition, the gratuitous capital reduction and disposition of surplus (replenishment of deficit) carried out on 6 August 2021 reduced stated capital by ¥6,302.191 million and capital surplus by ¥2,557.316 million, while increasing retained earnings by ¥8,859.508 million.」

    The results of the replenishment of the deficit through the gratuitous capital reduction and disposition of surplus that became effective on 6 August 2021, as well as the increase in retained earnings, are reconfirmed.
  8. FY2022-Q1AchievedAnnual report

    「It became effective on 6 August 2021.」

    The capital reduction, reduction of capital reserve and replenishment of the retained earnings deficit using ¥8,859 million of other capital surplus became effective on 6 August 2021, and the plan was implemented.
  9. FY2021First statedAnnual report

    「The purpose of reducing the amounts of stated capital and capital reserve and disposing of surplus is to replenish the deficit in retained earnings currently arising, strengthen the Company's financial position, and secure flexibility and agility in its future capital policy.」

    As a subsequent event, the Company disclosed a plan to reduce stated capital by ¥6,302 million and capital reserve by ¥2,110 million, and appropriate ¥8,859 million of other capital surplus to replenish the deficit in retained earnings. The effective date was scheduled for 6 August 2021.
Moved together

"Raising Funds for Cell Therapy Product Development and Clinical Trials through the 12th Series of Stock Acquisition Rights" moved the same way as this thread, in the same document, in 4 of its 9 moves.

444333★123456
  1. ★This thread
  2. 1Raising Funds for Cell Therapy Product Development and Clinical Trials through the 12th Series of Stock Acquisition Rights4×
  3. 2Research Support Business Segment Turning Profitable4×
  4. 3Development and Supply of an iPS Cell Bank for Clinical Applications4×
  5. 4Differentiation through a broad lineup of research reagents, cell products and contract services3×
  6. 5Exclusive development and marketing of Stemchymal® in Japan3×
  7. 6Persistent losses as upfront investment and R&D expenses precede revenue generation3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.